Brokers Set Expectations for Stevanato Group Q1 Earnings

Stevanato Group S.p.A. (NYSE:STVN) – Research analysts at William Blair lowered their Q1 2026 earnings estimates for Stevanato Group in a report released on Friday, May 9th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $0.12 for the quarter, down from their previous estimate of $0.13. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Stevanato Group’s current full-year earnings is $0.50 per share. William Blair also issued estimates for Stevanato Group’s Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.18 EPS and Q4 2026 earnings at $0.27 EPS.

STVN has been the topic of several other research reports. UBS Group cut their price target on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a report on Friday, March 7th. Stephens upgraded shares of Stevanato Group to a “strong-buy” rating in a report on Monday, April 21st. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($28.88).

Stevanato Group Trading Up 6.4%

NYSE STVN opened at €23.92 ($26.88) on Monday. Stevanato Group has a one year low of €16.56 ($18.61) and a one year high of €24.90 ($27.98). The company’s 50 day moving average price is €21.12 and its 200 day moving average price is €21.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 50.89, a PEG ratio of 7.18 and a beta of 0.51.

Stevanato Group (NYSE:STVN) last released its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million.

Institutional Trading of Stevanato Group

Hedge funds have recently made changes to their positions in the company. M&T Bank Corp purchased a new stake in shares of Stevanato Group during the fourth quarter valued at approximately $572,000. Mutual of America Capital Management LLC purchased a new stake in shares of Stevanato Group during the fourth quarter valued at approximately $13,848,000. Advantage Alpha Capital Partners LP raised its stake in shares of Stevanato Group by 27.3% during the fourth quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company’s stock valued at $6,403,000 after purchasing an additional 63,041 shares during the period. Allianz SE purchased a new stake in shares of Stevanato Group during the fourth quarter valued at approximately $748,000. Finally, Zions Bancorporation N.A. raised its stake in shares of Stevanato Group by 29.7% during the fourth quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company’s stock valued at $1,482,000 after purchasing an additional 15,555 shares during the period.

Stevanato Group Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Stockholders of record on Thursday, June 5th will be paid a dividend of $0.0613 per share. The ex-dividend date is Thursday, June 5th. This represents a dividend yield of 0.3%. This is a positive change from Stevanato Group’s previous annual dividend of $0.05. Stevanato Group’s dividend payout ratio (DPR) is currently 11.76%.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.